Liminatus Pharma股價在聘請Digital Offering進行孖展後飆升

英為財情

2025/07/24

Investing.com -- Liminatus Pharma Inc (NASDAQ:LIMN)股價跳漲26.5%，此前這家臨床前階段的生物製藥公司宣佈已聘請Digital Offering LLC作為其潛在戰略性孖展的獨家配售代理。該公司專注於開發靶向癌症免疫療法，表示此次合作支持其此前披露的數字資產財庫戰略評估。Liminatus正在評估現代金融工具以加強其資本結構，潛在的孖展計劃可能...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554810427"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554810427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554810427?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-24 23:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554810427","market":"sh","top_or_hot":-1,"title":"Liminatus Pharma股價在聘請Digital Offering進行孖展後飆升","media":"英為財情","content":"<div>\n<p>Investing.com -- Liminatus Pharma Inc (NASDAQ:LIMN)股價跳漲26.5%，此前這家臨床前階段的生物製藥公司宣佈已聘請Digital Offering LLC作為其潛在戰略性孖展的獨家配售代理。\n該公司專注於開發靶向癌症免疫療法，表示此次合作支持其此前披露的數字資產財庫戰略評估。Liminatus正在評估現代金融工具以加強其資本結構，潛在的孖展計劃可能...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2901738\">網頁鏈接</a>\n\n</div>\n","source":"investing_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Liminatus Pharma股價在聘請Digital Offering進行孖展後飆升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLiminatus Pharma股價在聘請Digital Offering進行孖展後飆升\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">英為財情</strong><span class=\"h-time small\">2025-07-24 23:50</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com -- Liminatus Pharma Inc (NASDAQ:LIMN)股價跳漲26.5%，此前這家臨床前階段的生物製藥公司宣佈已聘請Digital Offering LLC作為其潛在戰略性孖展的獨家配售代理。\n該公司專注於開發靶向癌症免疫療法，表示此次合作支持其此前披露的數字資產財庫戰略評估。Liminatus正在評估現代金融工具以加強其資本結構，潛在的孖展計劃可能...</p>\n\n<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2901738\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://cn.investing.com/news/stock-market-news/article-93CH-2901738\">英為財情</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LIMN","symbol_name":"Liminatus Pharma LLC","start_time":0,"source_url":"https://cn.investing.com/news/stock-market-news/article-93CH-2901738","article_id":"2554810427","we_media_id":null,"thumbnails":[],"rights":{"source":"investing_news","url":"https://cn.investing.com/news/stock-market-news/article-93CH-2901738","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554810427","pubTimestamp":1753372200,"columns":[],"sourceInfo":{"source_id":"investing_news","name":"英为财情新闻"},"weMediaInfo":null,"summary":"Investing.com -- Liminatus Pharma Inc 股價跳漲26.5%，此前這家臨床前階段的生物製藥公司宣佈已聘請Digital Offering LLC作為其潛在戰略性融資的獨家配售代理。Digital Offering作為一家在FINRA和SEC註冊的經紀交易商，將協助Liminatus尋找機構投資者和專注於數字資產的投資者，並構建合規的融資解決方案。\"在Liminatus，我們的核心使命是推進癌症的變革性免疫療法，\"Liminatus的首席執行官Chris Kim表示。與Digital Offering合作使我們能夠以紀律性和前瞻性探索戰略融資機會——無論是在傳統市場還是在不斷發展的數字資產領域。","collect":0,"end_time":0,"defaultTopTitle":"investing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LIMN":"Liminatus Pharma LLC","BK4139":"生物科技"},"translate_title":"Liminatus Pharma stock surges after hiring Digital Offering for funding","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LIMN":1},"content_text":"Investing.com -- Liminatus Pharma Inc (NASDAQ:LIMN)股價跳漲26.5%，此前這家臨床前階段的生物製藥公司宣佈已聘請Digital Offering LLC作為其潛在戰略性融資的獨家配售代理。\n該公司專注於開發靶向癌症免疫療法，表示此次合作支持其此前披露的數字資產財庫戰略評估。Liminatus正在評估現代金融工具以加強其資本結構，潛在的融資計劃可能包括可轉換債券、與股權掛鈎的證券或其他符合美國證券法的替代工具。\nDigital Offering作為一家在FINRA和SEC註冊的經紀交易商，將協助Liminatus尋找機構投資者和專注於數字資產的投資者，並構建合規的融資解決方案。\n\"在Liminatus，我們的核心使命是推進癌症的變革性免疫療法，\"Liminatus的首席執行官Chris Kim表示。\"在我們朝着這一目標努力的同時，我們也在積極採取措施加強我們的資本戰略。與Digital Offering合作使我們能夠以紀律性和前瞻性探索戰略融資機會——無論是在傳統市場還是在不斷發展的數字資產領域。\"\n該公司強調，目前尚未敲定任何融資交易，任何潛在的資本交易仍需董事會批准並完全符合監管要求。此公告不構成在任何司法管轄區出售證券的要約或購買證券要約的邀請。\n\n本文由人工智能協助翻譯。更多信息，請參見我們的使用條款。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}